BR0308088A - ácidos alfa-iminocarboxìlicos substituìdos com n, cìclicos, para a inibição seletiva de colagenase - Google Patents

ácidos alfa-iminocarboxìlicos substituìdos com n, cìclicos, para a inibição seletiva de colagenase

Info

Publication number
BR0308088A
BR0308088A BR0308088-9A BR0308088A BR0308088A BR 0308088 A BR0308088 A BR 0308088A BR 0308088 A BR0308088 A BR 0308088A BR 0308088 A BR0308088 A BR 0308088A
Authority
BR
Brazil
Prior art keywords
disease
collagenase
cyclic
selective inhibition
chronic
Prior art date
Application number
BR0308088-9A
Other languages
English (en)
Inventor
Petra Stahl
Reinhard Kirsch
Sven Ruf
Volkmar Wehner
Klaus-Ulrich Weithmann
Original Assignee
Aventis Pharma Deutschalnd Gmb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschalnd Gmb filed Critical Aventis Pharma Deutschalnd Gmb
Publication of BR0308088A publication Critical patent/BR0308088A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"áCIDOS ALFA-IMINOCARBOXìLICOS SUBSTITUìDOS COM N, CìCLICOS, PARA A INIBIçãO SELETIVA DE COLAGENASE". A presente invenção refere-se a compostos da fórmula (I) são apropriados para produção de medicamentos para profilaxia e terapia de doenças, de cuja evolução participa uma atividade intensificada da metalo-proteinase de matriz 13. às mesmas pertencem doenças tal como doença articular degenerativa, por exemplo, osteoartroses, espondiloses, perda de cartilagem, após trauma de articulações ou após longa imobilização de articulações, depois de lesões de menisco ou patela, ou rupturas de ligamentos, ou uma doença do tecido conjuntivo, tal como colagenoses, doenças periodontais, distúrbios de cura de feridas ou uma doença crónica do aparelho locomotor, tal como artrites agudas ou crónicas, inflamatórias,de origem imunológica ou metabólica, artropatias, mialgias e distúrbios do metabolismo ósseo ou uma ulceração, aterosclerose ou estenose ou uma doença inflamatória ou uma doença cancerosa, formação de metástases de tumores, caquexia, anoxeria ou choque séptico.
BR0308088-9A 2002-03-02 2003-02-18 ácidos alfa-iminocarboxìlicos substituìdos com n, cìclicos, para a inibição seletiva de colagenase BR0308088A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10209299A DE10209299A1 (de) 2002-03-02 2002-03-02 Cyclische N-substituierte alpha-Iminocarbonsäuren zur selektiven Inhibierung von Kollagenase
PCT/EP2003/001596 WO2003074489A1 (de) 2002-03-02 2003-02-18 Cyclische n-substituierte alpha-iminocarbonsäuren zur selektiven inhibierung von kollagenase

Publications (1)

Publication Number Publication Date
BR0308088A true BR0308088A (pt) 2004-12-21

Family

ID=27762622

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308088-9A BR0308088A (pt) 2002-03-02 2003-02-18 ácidos alfa-iminocarboxìlicos substituìdos com n, cìclicos, para a inibição seletiva de colagenase

Country Status (11)

Country Link
EP (1) EP1483244B1 (pt)
JP (1) JP4520744B2 (pt)
AR (1) AR038857A1 (pt)
AU (1) AU2003214063A1 (pt)
BR (1) BR0308088A (pt)
CA (1) CA2477474C (pt)
DE (1) DE10209299A1 (pt)
MX (1) MXPA04007844A (pt)
PE (1) PE20030883A1 (pt)
TW (1) TW200400178A (pt)
WO (1) WO2003074489A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005002500A1 (de) * 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1131215C (zh) * 1995-11-13 2003-12-17 赫彻斯特股份公司 环和杂环N－取代的α－亚氨基异羟肟酸和羧酸

Also Published As

Publication number Publication date
EP1483244B1 (de) 2013-04-10
CA2477474C (en) 2010-11-16
JP2005528350A (ja) 2005-09-22
PE20030883A1 (es) 2003-12-05
EP1483244A1 (de) 2004-12-08
WO2003074489A1 (de) 2003-09-12
CA2477474A1 (en) 2003-09-12
TW200400178A (en) 2004-01-01
AU2003214063A1 (en) 2003-09-16
MXPA04007844A (es) 2004-10-15
DE10209299A1 (de) 2003-09-18
JP4520744B2 (ja) 2010-08-11
AR038857A1 (es) 2005-01-26

Similar Documents

Publication Publication Date Title
BR0116096A (pt) Composto, composição farmacêutica, e, métodos para tratar uma condição ou doença inflamatória ou imune em um paciente, para tratar uma condição ou doença mediada por cxcr3 em um paciente, e para a modulação da função de cxcr3 em uma célula
BRPI0407919A (pt) pirrolopirimidinas espiro-substituìdas
BR0015026A (pt) Indóis substituìdos para a modulação da atividade de nfkb
WO2005073236A3 (de) Thieno-iminosäure-derivate als inhibitoren von matrix-metalloproteinasen
BR0010555A (pt) Inibidores de neuraminidases
BR0210008A (pt) Derivados de feniluréia substituìdos com carboxamida, processos para produção dos mesmos como medicamentos
ITPD20020064A1 (it) Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem
UY27167A1 (es) Inhibidores de piridina de metaloproteinasas de la matriz
BRPI0418004A (pt) composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis
ATE329587T1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
HK1106161A1 (en) Amide derivatives of hyaluronic acid in osteoarthrosis
BR0310087A (pt) Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas
BR9815596A (pt) Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase
BR0306738A (pt) Processo e aparelho para preparar partìculas cristalinas de uma substância, população de partìculas, e, composição farmacêutica
AR022423A1 (es) Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
BR0200341A (pt) Bifenilsulfonamidas proveitosas como inibidores de metaloproteases da matriz
SV1997000036A (es) Inhibisores de matrices metaloproteasas mediante acidos biaril oxobutiricos sustituidos
BR0308088A (pt) ácidos alfa-iminocarboxìlicos substituìdos com n, cìclicos, para a inibição seletiva de colagenase
BR0315055A (pt) Diamidas de ácido pirimidin-4,6-dicarboxìilco para a inibição seletiva de colagenases
EA201170369A1 (ru) Карбоксиэтилированные полисульфаты циклодекстрина, подходящие для применения в качестве лекарственных средств
BRPI0414594A (pt) derivados de iminoácidos bicìclicos como inibidores de matriz de metaloproteinases
PA8571601A1 (es) Inhibidores selectivos de la ciclooxigenasa-2
BR9910092A (pt) Inibidores de beta-aminoácido substituìdo de metionina aminopeptidase-2
BRPI0606493A2 (pt) derivados de tetrahidrofurano para uso como inibidores das metaloproteinases da matriz
SV1997000037A (es) Inhibisor de matrices de metaloproteasas mediante compuestos sustituidos de fenalquilo,

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8 E 13 DA LPI

B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.